Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Chronic Plaque-Type Psoriasis
- Conditions
- Psoriasis
- First Posted Date
- 2004-12-06
- Last Posted Date
- 2006-08-31
- Lead Sponsor
- Novartis
- Registration Number
- NCT00098189
Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection
- Conditions
- ChickenpoxHerpes Zoster
- First Posted Date
- 2004-12-03
- Last Posted Date
- 2007-09-26
- Lead Sponsor
- Novartis
- Target Recruit Count
- 76
- Registration Number
- NCT00098046
- Locations
- 🇵🇦
Novartis Investigational Site, David, Chiriqui, Panama
🇺🇸Columbia University Medical Center, New York, New York, United States
Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity
- Conditions
- Primary Insulin HypersecretionObesity
- First Posted Date
- 2004-10-15
- Last Posted Date
- 2009-09-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 160
- Registration Number
- NCT00094146
- Locations
- 🇺🇸
University of Wisconsin Beers-Murphy Clinical Nutrition Clinic, Madison, Wisconsin, United States
🇺🇸New Orleans Center for Clinical Research, New Orleans, Louisiana, United States
🇺🇸University of Tennessee, Memphis, Tennessee, United States
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
- Conditions
- Hypercalcemia of MalignancyLung CancerMetastatic CancerPainUnspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-07-22
- Last Posted Date
- 2013-02-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 600
- Registration Number
- NCT00003884
- Locations
- 🇺🇸
Cancer Specialist of South Texas. P.A., Corpus Christi, Texas, United States
🇺🇸New England Medical Center Hospital, Boston, Massachusetts, United States
🇺🇸American Medical Research Institute, Inc., Atlanta, Georgia, United States
STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2004-05-26
- Last Posted Date
- 2013-01-03
- Lead Sponsor
- Novartis
- Registration Number
- NCT00006343
- Locations
- 🇺🇸
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
- Conditions
- Colorectal CancerDiarrhea
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2012-05-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 89
- Registration Number
- NCT00006269
- Locations
- 🇺🇸
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
🇺🇸Theradex, Princeton, New Jersey, United States
STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa
- Conditions
- Leukemia
- First Posted Date
- 2004-05-04
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Novartis
- Registration Number
- NCT00006053
- Locations
- 🇺🇸
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis
- Conditions
- Leukemia
- First Posted Date
- 2004-04-26
- Last Posted Date
- 2013-02-21
- Lead Sponsor
- Novartis
- Registration Number
- NCT00006475
- Locations
- 🇺🇸
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2004-04-02
- Last Posted Date
- 2014-01-31
- Lead Sponsor
- Novartis
- Registration Number
- NCT00006052
- Locations
- 🇺🇸
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2003-11-13
- Last Posted Date
- 2013-02-21
- Lead Sponsor
- Novartis
- Registration Number
- NCT00014638
- Locations
- 🇺🇸
Cancer Research Network, Inc., Hollywood, Florida, United States
🇺🇸Good Samaritan Medical Center, West Palm Beach, Florida, United States
🇺🇸Carle Cancer Center, Urbana, Illinois, United States